pellicle;n851603 said:
Hi
if you don't mind I think that it would fantastic if you could share some of this. I mean since its a question so much discussed and to my knowledge there are no other participants on this forum in such a position. It would be fantastic to hear actual experiences.
To start with stuff like:
why it was chosen (was it just a preference, did the Drs think that she was too frail to recover from regular aortic surgery)
So be careful with factoring in your addition of age at operation and likelyhood of redo ... if you are under 40 don't expect to get off lightly. There are many here who have reported taking tissue at under 50 and not getting more than 10 years out of it.
Opinions are one thing, but be careful about spreading mistruths.
Pellicle:
RE: TAVR
My aunt, at age 84 had TAVR (two years ago in February) along with 3 stents! Because of her age and other health issues i.e. on medication for a rare blood condition and because she was frail, they decided against standard OHS. I have a posted if anyone is interested in reading about it:
http://www.valvereplacement.org/foru...ecovery-period
RE: Longevity of Tissue Valves:
Here is a good research article abstract from 2010 that provides the mean age of re-operation for bioprosthetic aortic valves in individuals under 60.
They have a good sample size. I am not sure what type of biosprosthetic valves the patients had implanted, but read patient age, valve type and other co-morbidities play a role in re-operation rates.
If you are interested in reading the full article, here is the link.:
http://circ.ahajournals.org/content/...ppl_1/S75.full
"We examined the need for reoperation in 3975 patients who underwent first-time bioprosthetic aortic valve replacement (AVR) (n=3152) or mitral valve replacement (MVR) (n=823).
There were 895 patients below the age of 60 years at bioprosthesis implant (AVR, n=636; MVR, n=259).
The
median interval to reoperation following bioprosthetic AVR was 10.27 years (95% CI 8.48 to 12.08 years) in patients less than 40 years of age, and 11.48 years (95% CI 10.47 to 13.07 years) in patients between 40 and 60 years of age.
Notably, the median interval to reoperation was not reached in patients more than 60 years of age.
When
restricting the analyses to patients who had contemporary stented bioprostheses, the median interval to reoperation in patients between 40 and 60 years of age was 12.93 years (95% CI 11.10 to 15.76 years), and it was 7.74 years (95% CI 7.28 to 9.97 years) in patients less than 40 years of age (
Figure 1B).
Univariable risk factors associated with reoperation following AVR with a contemporary, stented bioprosthesis included age and concomitant CABG "